BackTasly Pharmaceutical Group , Ltd Overview

Tasly Pharmaceutical Group , Ltd Profit Margin

Latest profit margin for Tasly Pharmaceutical Group , Ltd: 15.3% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

11.21%
↑ 8.11% YoY

As of Sep 2026

Annual Profit Margin (TTM)

15.30%
↑ 16.30% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Tasly Pharmaceutical Group , Ltd (600535.SS) FAQ

Tasly Pharmaceutical Group , Ltd posts a profit margin of 15.3% as of September 2026. That compares with 13.15% in the prior-year period — up 16.3% year over year. That is above the sector sector average of 13.4%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tasly Pharmaceutical Group , Ltd's profit margin was 13.15%. The latest reading is 15.3% — a 16.3% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.4% is typical. Tasly Pharmaceutical Group , Ltd's 15.3% is higher that level. That is roughly 14.1% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Tasly Pharmaceutical Group , Ltd's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 15.3% as of September 2026; use YoY and peer views to separate noise from signal.

Context for 600535.SS's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.4%), and (3) consistency with growth and profitability. This page covers the first two; Tasly Pharmaceutical Group , Ltd's other metric pages and overview cover the third.